# EDGAR Filing Document

**Accession Number:** 0001626644
**File Stem:** 0001683168-26-004820
**Filing Date:** 2026-6
**Character Count:** 93485
**Document Hash:** 14e74f99b6d6409d0527244e5d136b43
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001683168-26-004820.hdr.sgml**: 20260612

**ACCESSION NUMBER**: 0001683168-26-004820

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 58

**CONFORMED PERIOD OF REPORT**: 20260430

**FILED AS OF DATE**: 20260612

**DATE AS OF CHANGE**: 20260612

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Odyssey Health, Inc.
- **CENTRAL INDEX KEY:** 0001626644
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 471022125
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0731

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-56196
- **FILM NUMBER:** 261087907

**BUSINESS ADDRESS:**
- **STREET 1:** 2300 WEST SAHARA AVENUE
- **STREET 2:** SUITE 800-#4012
- **CITY:** LAS VEGAS
- **STATE:** NV
- **ZIP:** 89102
- **BUSINESS PHONE:** 702-780-6559

**MAIL ADDRESS:**
- **STREET 1:** 2300 WEST SAHARA AVENUE
- **STREET 2:** SUITE 800-#4012
- **CITY:** LAS VEGAS
- **STATE:** NV
- **ZIP:** 89102

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Odyssey Group International, Inc.
- **DATE OF NAME CHANGE:** 20141128

?xml version='1.0' encoding='ASCII'? Odyssey Health, Inc. 10-Q

[**Table of Contents**](#toc)

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

_________________________________

**Form 10-Q**

_________________________________

☒ **&nbsp;&nbsp;&nbsp;&nbsp; QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended April 30, 2026**

**or**

☐ **&nbsp;&nbsp;&nbsp;&nbsp; TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; .**

**Commission File No. 000-56196**

____________________________________

**Odyssey Health, Inc.**

**(Exact name of registrant as specified in its charter)**

____________________________________

---

| | |
|:---|:---|
| **Nevada** | **47-1022125** |
| **(State or other jurisdiction of incorporation or organization)** | **(I.R.S. Employer Identification No.)** |

---

**2300 West Sahara Avenue, Suite 800 - #4012, Las Vegas, NV 89102**

(Address of principal executive offices, including zip code)

**(702) 780-6559**

(Registrant's telephone number, including area code)

**Securities registered pursuant to Section 12(b) of the Act: None**

---

| | | |
|:---|:---|:---|
| **Title of each Class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| N/A | N/A | N/A |

---

**Securities registered pursuant to Section 12(g) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each Class** | **Trading Symbol** | **Name of each exchange on which registered** |
| Common Stock ($0.001 par value) | ODYY | OTC |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;No ☐

Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one)

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes ☐&nbsp;&nbsp;&nbsp;&nbsp;No ☒

100,968,663 shares of common stock, par value $0.001 per share, outstanding as of June 12, 2026.

**ODYSSEY HEALTH, INC.** 

**FORM 10-Q**

**For the Quarter Ended April 30, 2026**

**INDEX**

---

| | | |
|:---|:---|:---|
|  |  | **Page** |
| [**PART I - FINANCIAL INFORMATION**](#q3_001) | [**PART I - FINANCIAL INFORMATION**](#q3_001) | [**PART I - FINANCIAL INFORMATION**](#q3_001) |
| Item 1 | [Financial Statements (Unaudited)](#q3_002) | 3 |
|  | [Condensed Consolidated Balance Sheets](#q3_003) | 3 |
|  | [Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)](#q3_004) | 4 |
|  | [Condensed Consolidated Statements of Changes in Stockholders' Deficit](#q3_005) | 5 |
|  | [Condensed Consolidated Statements of Cash Flows](#q3_006) | 6 |
|  | [Notes to Condensed Consolidated Financial Statements](#q3_007) | 7 |
| Item 2 | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#q3_008) | 19 |
| Item 3 | [Quantitative and Qualitative Disclosures About Market Risk](#q3_009) | 24 |
| Item 4 | [Controls and Procedures](#q3_010) | 24 |
| [**PART II - OTHER INFORMATION**](#q3_011) | [**PART II - OTHER INFORMATION**](#q3_011) | [**PART II - OTHER INFORMATION**](#q3_011) |
| Item 1A | [Risk Factors](#q3_012) | 26 |
| Item 5 | [Other Information](#q3_013) | 26 |
| Item 6 | [Exhibits](#q3_014) | 26 |
| [Signatures](#q3_015) | [Signatures](#q3_015) | 27 |

---

**PART I - FINANCIAL INFORMATION**

**Item 1.** ***Financial Statements***

**Odyssey Health, Inc. and Subsidiaries**

**Condensed Consolidated Balance Sheets**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **April 30,**<br>**2026** | **July 31,**<br>**2025** |
| **Assets** |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;Cash | $297806 | $19084 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets, net | 75973 | 30639 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 373779 | 49723 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $373779 | $49723 |
| **Liabilities and Stockholders' Deficit** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable and accrued wages | $1484536 | $1615357 |
| &nbsp;&nbsp;&nbsp;Accounts payable and accrued wages, officers | 1854617 | 1858443 |
| &nbsp;&nbsp;&nbsp;Accrued interest | 586351 | 421440 |
| &nbsp;&nbsp;&nbsp;Asset purchase liability | 1125026 | 1125026 |
| &nbsp;&nbsp;&nbsp;Notes payable, officers and directors | 100000 | 100000 |
| &nbsp;&nbsp;&nbsp;Notes payable, net of unamortized debt discounts | 2542321 | 1884155 |
| &nbsp;&nbsp;&nbsp;Derivative liability | 2430585 | – |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 10123436 | 7004421 |
| Commitments and contingencies (Note 3) |  |  |
| Stockholders' deficit: |  |  |
| &nbsp;&nbsp;&nbsp;Preferred stock, $0.001 par value, 100,000,000 shares authorized, no shares issued or outstanding as of April 30, 2026 and July 31, 2025 |  |  |
| &nbsp;&nbsp;&nbsp;Common stock, $0.001 par value, 500,000,000 shares authorized, 100,968,663 and 96,709,763 shares issued and outstanding as of April 30, 2026 and July 31, 2025, respectively | 100969 | 96710 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 56214391 | 55694429 |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (66065017) | (62745837) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' deficit | (9749657) | (6954698) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' deficit | $373779 | $49723 |

---

 

*The accompanying notes are an integral part of these condensed consolidated financial statements.*

**Odyssey Health, Inc. and Subsidiaries**

**Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Three Months Ended<br> April 30,** | **For the Three Months Ended<br> April 30,** | **For the Nine Months Ended<br> April 30,** | **For the Nine Months Ended<br> April 30,** |
|  | **2026** | **2025** | **2026** | **2025** |
| General and administrative expense | $297554 | $129055 | $782687 | $865075 |
| Loss from operations | (297554) | (129055) | (782687) | (865075) |
| Loss from change in fair value of Oragenics, Inc. common stock |  | (61357) |  | (432053) |
| Interest expense | (527551) | (61395) | (1035315) | (193611) |
| Financing costs |  |  | (3080023) |  |
| Change in fair value of derivative liability | 1505581 |  | 1503652 |  |
| Gain on extinguishment of accounts payable | 85369 |  | 85369 |  |
| Other income (expense), net | 45 | 64 | (10177) | (36) |
| Net income (loss) and comprehensive income (loss) | 765890 | (251743) | (3319181) | (1490775) |
| Basic net income (loss) and comprehensive income (loss) per share | $0.01 | $0.00 | $(0.03) | $(0.01) |
| Diluted net income (loss) and comprehensive income (loss) per share | $0.01 | $0.00 | $(0.03) | $(0.01) |
| Shares used for basic net income (loss) comprehensive income (loss) per share | 108031419 | 104709763 | 107299314 | 104709763 |
| Shares used for diluted net income (loss) comprehensive income (loss) per share | 186674907 | 104709763 | 107299314 | 104709763 |

---

 

 

*The accompanying notes are an integral part of these condensed consolidated financial statements.*

 

 

 

**Odyssey Health, Inc. and Subsidiaries**

**Condensed Consolidated Statements of Changes in Stockholders' Deficit**

**(Unaudited)**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | | | |
|  | **Shares** | **Dollars** | **Additional Paid-In**<br>**Capital** | **Accumulated**<br>**Deficit** | **Total Stockholders'**<br> **Deficit** |
| **Balances, July 31, 2025** | 96709763 | $96710 | $55694429 | $(62745837) | $(6954698) |
| Common stock issued for conversion of accrued interest and fees | 1144000 | 1144 | 81224 |  | 82368 |
| Common stock issued for conversion of outstanding principal | 2000000 | 2000 | 142000 |  | 144000 |
| Warrants issued in debt financing |  |  | 56589 |  | 56589 |
| Net loss | – | – | – | (483447) | (483447) |
| **Balances, October 31, 2025** | 99853763 | 99854 | 55974242 | (63229284) | (7155188) |
| Warrants issued in debt financing |  |  | 160992 |  | 160992 |
| Net loss | **–** | **–** | **–** | (3601623) | (3601623) |
| **Balances, January 31, 2026** | 99853763 | 99854 | 56135234 | (66830907) | (10595819) |
| Common stock issued for conversion of accrued interest and fees | 419900 | 420 | 29812 |  | 30231 |
| Common stock issued for conversion of outstanding principal, accrued interest and fees | 695000 | 695 | 49345 |  | 50040 |
| Net income | – | – | – | 765890 | 765890 |
| **Balances, April 30, 2026** | 100968663 | $100969 | $56214391 | $(66065017) | $(9749657) |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | | | |
|  | **Shares** | **Dollars** | **Additional Paid-In**<br>**Capital** | **Accumulated**<br>**Deficit** | **Total Stockholders'**<br> **Deficit** |
| **Balances, July 31, 2024** | 96709763 | $96710 | $55572687 | $(61003146) | $(5333749) |
| Stock-based compensation |  |  | 60487 |  | 60487 |
| Warrants issued in debt financing |  |  | 13343 |  | 13343 |
| Net loss | – | – | – | (1018906) | (1018906) |
| **Balances, October 31, 2024** | 96709763 | 96710 | 55646517 | (62022052) | (6278825) |
| Stock-based compensation |  |  | 36131 |  | 36131 |
| Net loss | **–** | **–** | **–** | (220126) | (220126) |
| **Balances, January 31, 2025** | 96709763 | 96710 | 55682648 | (62242178) | (6462820) |
| Stock-based compensation |  |  | 11781 |  | 11781 |
| Net loss | – | – | – | (251743) | (251743) |
| **Balances, April 30, 2025** | 96709763 | $96710 | $55694429 | $(62493921) | $6702782 |

---

 

*The accompanying notes are an integral part of these condensed consolidated financial statements.*

**Odyssey Health, Inc. and Subsidiaries**

**Condensed Consolidated Statements of Cash Flows**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **For the Nine Months Ended April 30,** | **For the Nine Months Ended April 30,** |
|  | **2026** | **2025** |
| **Cash flows from operating activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Net loss | $(3319181) | $(1490775) |
| &nbsp;&nbsp;&nbsp;Adjustments to reconcile net loss to net cash flows used in operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation |  | 108399 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Allowance for research and development rebate due |  | 22625 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financing costs | 3080023 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of derivative liability | (1503652) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of debt discount and closing costs | 721463 | 43464 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss from change in fair value of Oragenics, Inc. common stock |  | 432053 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financing costs paid with issuance of common stock | 5250 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on extinguishment of accounts payable | (85369) |  |
| &nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Increase) in prepaid expenses and other current assets | (45334) | (32234) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increase (decrease) in accounts payable and accrued wages | (45452) | 189973 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increase in accounts payable and accrued wages, officers | (3826) | 279966 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increase in accrued interest | 309300 | 147336 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net cash used in operating activities** | (886778) | (299193) |
| **Cash flows from financing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from notes payable | 1165500 | 300000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net cash provided by financing activities** | 1165500 | 300000 |
| **Increase in cash and cash equivalents** | 278722 | 807 |
| Cash and cash equivalents: |  |  |
| &nbsp;&nbsp;&nbsp;Beginning of period | 19084 | 2379 |
| &nbsp;&nbsp;&nbsp;End of period | $297806 | $3186 |
| **Supplemental disclosure of cash flow information:** |  |  |
| Cash paid for interest | $4552 | $2811 |
| **Supplemental disclosure of non-cash information:** |  |  |
| &nbsp;&nbsp;&nbsp;Common stock issued for conversion of outstanding principal | $194040 | $– |
| &nbsp;&nbsp;&nbsp;Common stock issued for conversion of accrued interest and fees | 107350 |  |
| &nbsp;&nbsp;&nbsp;Warrants issued in debt financing | 217581 | 13343 |
| &nbsp;&nbsp;&nbsp;Original issue discount on debt and closing costs on notes payable | 2085771 |  |
| &nbsp;&nbsp;&nbsp;Rent offset payment applied to principal on maintenance note payable | 62680 |  |
| &nbsp;&nbsp;&nbsp;Rent offset payment applied to accrued interest on notes payable | 30492 |  |
| &nbsp;&nbsp;&nbsp;Debt discount recognized on notes payable associated with derivative liability | 1184943 |  |

---

*The accompanying notes are an integral part of these condensed consolidated financial statements.*

**Odyssey Health, Inc. and Subsidiaries**

**Notes to Condensed Consolidated Financial Statements**

**(Unaudited)**

**Note 1. Basis of Presentation, Nature of Operations and Going Concern**

***Basis of Presentation***

The accompanying condensed consolidated financial information of Odyssey Health, Inc. and our wholly-owned subsidiaries, Odyssey Medical Devices, Inc. and Odyssey Group International Australia, Pty Ltd, is unaudited and has been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). All intercompany balances and transactions have been eliminated. Such information reflects all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the condensed consolidated financial position, results of operations and cash flows for the interim periods. The consolidated financial information as of July 31, 2025, is derived from our Annual Report on Form 10-K for the year ended July 31, 2025. The condensed consolidated financial statements included herein should be read in conjunction with the consolidated financial statements and the notes thereto included in our 2025 Annual Report on Form 10-K filed with the SEC on October 29, 2025. The condensed consolidated results of operations for the interim periods presented are not necessarily indicative of the results to be expected for the full year.

***Significant Accounting Policies***

Other than as described below, our significant accounting policies have not changed during the nine months ended April 30, 2026 from those disclosed in our Annual Report on Form 10-K for the year ended July 31, 2025.

 ****

**Segment Reporting**

We operate as one reportable segment under ASC 280, *Segment Reporting*. The Chief Operating Decision Maker, reviews and evaluates financial information and allocates resources on a consolidated basis when making operating decisions and assessing performance.

**Accounting for Derivative Liabilities**

We have derivative liabilities related to outstanding debt with a variable conversion features. We accounted for the fair value of the derivative liability utilizing a Black-Scholes pricing model upon inception and mark it to fair value using the Black-Scholes pricing model as of the end of each reporting period with the change in fair value being accounted for in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) in the period incurred. See also Notes 4 and 5.

**Accounting for Extinguishment of Accounts Payable**

During the third quarter of Fiscal 2026, certain vendors forgave the accounts payable owed to them by us. Pursuant to Accounting Standards Codification ("ASC") 405-20 Liabilities – Extinguishment of Liabilities, we account for the forgiveness of accounts payable as the extinguishment of debt and record the gain as Gain on extinguishment of accounts payable in the period of forgiveness.

***Reclassifications***

We have reclassified, combined or separately disclosed certain amounts in the prior year's condensed consolidated financial statements and accompanying footnotes to conform with the current year's presentation. These changes consisted of the following:

&nbsp;&nbsp;&nbsp;&nbsp;· combining Accounts payable and Accrued wages on the Condensed Consolidated Balance Sheets and Condensed
Consolidated Statements of Cash Flows;

&nbsp;&nbsp;&nbsp;&nbsp;· separating Accounts payable and accrued wages, officers from Accounts payable and accrued wages on the
Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Cash Flows; and

&nbsp;&nbsp;&nbsp;&nbsp;· combining Stock-based compensation with General and administrative expense on the Condensed Consolidated
Statements of Operations and Comprehensive Income (Loss) in order to conform with the current period presentation.

There was no effect on the reported Net income (loss) for the periods reported.

 ****

***Nature of Operations***

Our corporate mission is to create or acquire distinct assets, intellectual property, and technologies with an emphasis on acquisition targets that have superior clinical utility and serve an unmet medical need. Our business model is to develop or acquire medical-related products, engage third parties to help develop such products, complete clinical trials, and manufacture products according to U. S. Food and Drug Administration ("FDA") regulations. We have two different technologies in development; the CardioMap heart monitoring and screening device and the Save-A-Life choking rescue device.

We intend to acquire other technologies and assets and plan to be a trans-disciplinary product development company involved in the discovery, development and commercialization of products and technologies that may be applied over various medical markets. We plan to license, improve and/or develop our products and identify and select distribution channels. We intend to establish agreements with distributors to get products to market quickly as well as to undertake and engage in our own direct marketing efforts. We will determine the most effective method of distribution for each unique product that we include in our portfolio. We will engage third-party research and development firms who specialize in the creation of our products to assist us in the development of our own products, and we will apply for trademarks and patents once we have developed proprietary products.

We are not currently selling or marketing any products, as our products are in development, and FDA clearance or approval to market our products will be required to sell in the United States. In addition, we would require additional European Union or country specific clearance or approvals to sell internationally.

 ****

***Going Concern***

We did not recognize any revenues for the nine months ended April 30, 2026 or the year ended July 31, 2025, and we had an accumulated deficit of $66,065,017 as of April 30, 2026. For the foreseeable future, we expect to experience continuing operating losses and negative cash flows from operations. As of April 30, 2026, we had current liabilities of $10,123,436, current assets of $373,779, and a working capital deficit of $9,749,657. At April 30, 2026, based on current projections and anticipated funding sources, we believe we have sufficient working capital to meet our operating expenses through the end of Fiscal 2026, subject to the risks and uncertainties described herein.

The operating deficit and negative working capital at April 30, 2026, indicate substantial doubt about our ability to continue as a going concern. Our continued existence depends on the success of our efforts to raise additional capital necessary to meet our obligations as they come due and to obtain sufficient capital to execute our business plan. We may obtain capital primarily through issuances of debt or equity or entering into collaborative arrangements with corporate partners. There can be no assurance that we will be successful in completing additional financing or collaboration transactions or, if financing is available, that it can be obtained on commercially reasonable terms. If we are not able to obtain the additional financing on a timely basis, we may be required to scale down or perhaps even cease operations.

The issuance of additional equity securities could result in a significant dilution in the equity interests of our current stockholders. Obtaining commercial loans, assuming those loans would be available, would increase our liabilities and future cash commitments. Our financial statements do not include adjustments that might result from the outcome of this uncertainty.

We are continually adjusting our business plan to reflect our current liquidity expectations. If we are unable to raise additional capital, secure additional debt financing, secure additional equity financing, secure a strategic partner, reduce our operating expenditures, or seek bankruptcy protection, we will adjust our business plan. Given our recurring losses, negative cash flow, and accumulated deficit, there is substantial doubt about our ability to continue as a going concern.

**Note 2. New Accounting Pronouncements**

***ASU 2023-09***

In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures*, which enhances the transparency of income tax disclosures by expanding annual disclosure requirements related to the rate reconciliation and income taxes paid. The amendments will be effective for our July 31, 2026 fiscal year end financial statements. The amendments should be applied on a prospective basis. Retrospective application is permitted. We are currently evaluating this ASU to determine its impact on our disclosures and do not expect the amendments to have a material effect on our financial statements.

***ASU 2024-03***

In November 2024, the FASB issued ASU 2024-03, *Comprehensive Income (Topic 220): Disaggregation of Income Statement Expense*, related to the disaggregation of certain income statement expenses. The amendments in this update require public entities to disclose incremental information related to purchases of inventory, team member compensation and depreciation, which will provide investors the ability to better understand entity expenses and make their own judgements about entity performance. The amendments in this update are effective for fiscal years beginning after December 15, 2026. We plan to adopt this pronouncement and make the necessary updates to our disclosures for the year ending July 31, 2027, and, aside from these disclosure changes, we do not expect the amendments to have a material effect on our financial statements.

**Note 3. Commitments and Contingencies**

**Master Technology and Sub-License Agreement**

On October 14, 2025, we entered into a Master Technology and Sub-license Agreement (the "Agreement") with NeuRX Health, Inc. ("NeuRX"). Pursuant to the Agreement, we entered into a sub-licensing agreement for exclusive, worldwide rights to BreastCheck®, a non-invasive test for breast abnormalities. The Agreement closed April 21, 2026. Terms included worldwide license to the technology, a royalty agreement, sublicense agreement and material transfer agreement.

On May 6, 2026, we received formal written notice from NeuRX, advising us that NeuRX was in breach of its contractual obligations with Davion Healthcare Plc ("Davion"). Specifically, NeuRX failed to obtain Davion's required approval prior to sublicensing the BreastCheck product to us. As a result, the notice stated that the Agreement between us and NeuRX was immediately cancelled. See also Note 11.

**Note 4. Fair Value Measurements** 

The fair value of financial assets and liabilities are determined utilizing a three-level framework as follows:

Level 1 – Observable inputs, such as unadjusted quoted prices in active markets, for substantially identical assets and liabilities.

Level 2 – Observable inputs other than quoted prices within Level 1 for similar assets and liabilities. These include quoted prices for similar assets and liabilities in active markets, quoted prices for identical assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data. If the asset or liability has a specified or contractual term, the input must be observable for substantially the full term of the asset or liability.

Level 3 – Unobservable inputs that are supported by little or no market activity, generally requiring a significant amount of judgment by management.

The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Further, although we believe our valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

We did not have any transfers of assets or liabilities measured at fair value on a recurring basis to or from Level 1, Level 2 or Level 3 during the nine months ended April 30, 2026, or the year ended July 31, 2025.

No changes were made to our valuation techniques during the quarter ended April 30, 2026.

We did not have any financial instruments carried at fair value at July 31, 2025. Financial instruments carried at fair value at April 30, 2026 included the following:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **April 30, 2026** | **April 30, 2026** | **April 30, 2026** | **April 30, 2026** |
|  | **Level 1** | **Level 2** | **Level 3** | **Total** |
| Derivative liability | $– | $– | $2430585 | $2430585 |

---

***Derivative Liabilities***

Derivative liabilities relate to the variable conversion feature embedded in our August 27, 2025 Securities Purchase Agreement, our November 13, 2025 Convertible Promissory Note and Maintenance Agreement, our November 13, 2025 Securities Purchase Agreement with Mast Hill Fund L.P. and our December 31, 2025 Second Tranche related to the November 13, 2025 Securities Purchase Agreement. See Note 5 for additional information. The fair value of our derivative liabilities as determined using the Black-Scholes pricing model utilizing the following inputs:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **August 27,**<br> **2025** | **October 31,**<br> **2025** | **November 13,**<br> **2025** | **December 31,**<br> **2025** | **April 30,**<br> **2026** |
| Expected stock price volatility | 228.72% | 251.16% | 236.31% | 234.40% | 191.32% - 220.93% |
| Risk free interest rate | 3.83% | 3.75% | 3.68% | 3.48% | 3.71% - 3.76% |
| Expected life of options (years) | 1.00 | 0.83 | 1.00 | 1.00 | .33-.67 |
| Expected dividend yield | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Exercise price | $0.024 | $0.058 | $0.058 | $0.026 | $0.048 |
| Stock price | $0.082 | $0.074 | $0.071 | $0.033 | $0.057 |

---

 ****

Changes in our derivative liabilities for the three and nine months ended April 30, 2026 were as follows:

---

| | |
|:---|:---|
| Balance at July 31, 2025 | $– |
| &nbsp;&nbsp;&nbsp;Derivative liability recognized | 647574 |
| &nbsp;&nbsp;&nbsp;Change in fair value of derivative liability | (422419) |
| Balance at October 31, 2025 | 225155 |
| &nbsp;&nbsp;&nbsp;Derivative liabilities recognized | 3286663 |
| &nbsp;&nbsp;&nbsp;Change in fair value of derivative liabilities | 424348 |
| Balance at January 31, 2026 | 3936166 |
| &nbsp;&nbsp;&nbsp;Change in fair value of derivative liabilities | (1505581) |
| Balance at April 30, 2026 | $2430585 |

---

See also Note 5.

 **

 ****

 **

 ****

***Fair Value of Current Assets and Current Liabilities***

The carrying values of Cash, Prepaid expenses and other current assets, Accounts payable and accrued wages, Accounts payable and accrued wages - officers, and Notes payable approximate their fair value due to their short maturities.

***Contingent Liability***

At April 30, 2026 and July 31, 2025, we had contingent consideration related to the acquisition of intellectual property, know-how and patents for an anti-choking, life-saving medical device in fiscal 2019. According to the agreement, we will make a one-time cash payment totaling $250,000 upon FDA clearance of the device. The fair value of the contingent consideration is reviewed quarterly and determined based on the current status of the project (Level 3). We determined the value was zero at both periods since it is not yet probable that we will file for FDA clearance.

 ****

**Note 5. Debt**

Our debt instruments consist of Convertible notes payable, officers and directors, Notes payable, and Convertible notes payable. All of our debt instruments are unsecured. Key terms of our various debt instruments are as follows:

 ****

***LGH Investments, LLC***

On September 15, 2025, and effective July 31, 2025, we entered into Amendment No. 10 to the Convertible Promissory Note pursuant to the Securities Purchase Agreement dated April 5, 2021, with LGH Investments, LLC ("LGH") (the "Note") which extended the maturity date of the Note to January 31, 2026.

On October 6, 2025, LGH converted $144,000 of their outstanding Note into 2,000,000 shares of our common stock at $0.072 per share.

On January 31, 2026, we entered into Amendment No. 11 to the Convertible Promissory Note to extend the maturity date to April 30, 2026.

On May 18, 2026, and effective April 30, 2026, we entered into Amendment No. 12 to the Convertible Promissory Note to extend the maturity date to September 30, 2026.

At April 30, 2026, we had $891,000 of principal and $312,104 of accrued interest outstanding pursuant to the Note.

***Accredited Investor Promissory Notes***

**$300,000 Promissory Note**

On August 14, 2024, we entered into a $300,000 promissory note (the "Note") with Peter D'Arruda, an accredited investor. The $300,000 was received on August 22, 2024. The Note has a one-year maturity, becoming due on August 22, 2025, and bears interest at the rate of 18% per annum. In addition, we issued the investor an immediately exercisable warrant to purchase 300,000 shares of our common stock at $0.10 per share that expires August 14, 2029, with a fair value of $13,343.

On August 14, 2025, this Note was amended to extend the maturity date to January 31, 2026.

On February 2, 2026 with an effective date of January 31, 2026, this Note was amended to extend the maturity date to January 31, 2027.

At April 30, 2026, $300,000 in principal and $92,315 in accrued interest remained outstanding.

**$100,000 Promissory Note**

On October 3, 2025, we entered into a $100,000 promissory note with an effective date of October 1, 2025, with Peter D'Arruda, an accredited investor. The $100,000 was received October 3, 2025. The note has a one-year maturity, becoming due on September 30, 2026, and bears interest at the rate of 18% per annum. In addition, we issued the investor an immediately exercisable warrant to purchase 100,000 shares of our common stock at $0.10 per share that expires September 30, 2030.

At April 30, 2026, $100,000 in principal and $10,455 in accrued interest remained outstanding.

**$50,000 Promissory Note**

On February 13, 2024, we entered into a six-month promissory note for $50,000, with Jonathan Lutz, an accredited investor, with an interest rate of 10% per annum, due August 11, 2024, and convertible into 20,000 shares of Oragenics, Inc. common stock currently held by us at the investor's option. In June 2024, this note was amended to provide for settlement of the note by issuing the accredited investor 30,000 shares of Oragenics common stock when the Oragenics preferred stock held by us is converted into Oragenics common stock.

On January 31, 2026, this note was amended to extend the maturity date to January 31, 2027.

At April 30, 2026, $50,000 in principal and $11,061in accrued interest remained outstanding.

***Mast Hill Fund L.P.***

Our unsecured debt instruments with Mast Hill have priority over our other unsecured debt in payment and performance. Our debt instruments with Mast Hill also have terms that restrict (a) distributions on our common stock, (b) stock repurchases, (c) the sale of any significant portion of our assets, and (d) certain advances and loans (all as defined within the Mast Hill debt agreements) without Mast Hill's written consent. Details of our debt instruments with Mast Hill are as follows:

**November 13, 2025 Convertible Promissory Note and Maintenance Agreement**

To consummate a separate November 13, 2025 Securities Purchase Agreement with Mast Hill, we entered into a maintenance agreement and a maintenance note with Mast Hill. The net effect from the maintenance agreement and note was an upfront expense of $330,030, which was recorded as a day one financing cost. The terms of the maintenance agreement and maintenance note are described below.

On November 13, 2025, we entered into a Maintenance Agreement with Mast Hill, pursuant to which we agreed to provide certain maintenance and related services for a commercial facility beginning November 13, 2025 and ending on the first business day of February 2034. In exchange, Mast Hill will pay us service fees (the "Fees") which currently total approximately $252,450 per year that is an offset to the principal and interest payable against the outstanding tranches. For financial statement presentation, future Fees receivable under the Maintenance Agreement will be offset against any debt owed to Mast Hill. As of April 30, 2026, $1,786,098 in future Fees receivable was offset against Notes payable.

In connection with the Maintenance Agreement, we issued to Mast Hill a convertible promissory note in the amount of $2,262,000 which bears interest at 10% per annum and is due November 13, 2026 (the "Maintenance Note") in exchange for the Fees to be received as described above. The Maintenance Note plus any accrued but unpaid interest is convertible at any time by Mast Hill into shares of our common stock at a price equal to 85% of the lowest volume weighted average price during the preceding 10 trading days.

Due to the variability of the conversion feature, it is valued separately from the underlying debt as an embedded conversion feature, which is a derivative liability. Using the Black-Scholes pricing model, we determined the fair value of the derivative liability to be $2,242,625 at inception. The fair value of the derivative liability in excess of the available face value of the note, net of all discounts from other sources, was recorded as a day one financing cost totaling $2,242,625. The derivative liability was revalued at April 30, 2026 with an estimated fair value of $1,589,795. Accordingly, a gain on change in fair value of derivative liabilities in the amount of $1,032,175 and $652,830 was recorded on our Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the three and nine months ended April 30, 2026. See also Note 4.

At April 30, 2026, there was $2,262,000 of principal and $103,495 of accrued interest outstanding pursuant to the Maintenance Note.

Pursuant to the terms of the Maintenance Note, we will remit any service fees received, less direct costs, to Mast Hill as payment on the Master Note tranches until paid in full or converted. The service fees under the Maintenance Agreement will not exceed the debt incurred under the Maintenance Note. Accordingly, we do not expect to record any revenues in the future under the Maintenance Agreement, as proceeds will only reduce the future Fees receivable, which are netted against Notes payable.

**November 13, 2025 Mast Hill Securities Purchase Agreement**

On November 13, 2025, we entered into a Securities Purchase Agreement (the "SPA") with Mast Hill. Pursuant to the terms of the SPA, we issued a promissory note with a maximum principal amount of up to $25,000,000 in multiple tranches (the "Master SPA Note"). Pursuant to the terms of the SPA, there is an original issue discount ("OID") of 10% on each tranche. Accordingly, the maximum proceeds to us, when considering the 10% OID, is $22,250,000 less any related costs and fees. The SPA Note is convertible at any time by Mast Hill into shares of our common stock at 85% of the lowest volume weighted average price during the preceding 10 trading days.

With each tranche, we will issue to Mast Hill common stock purchase warrants ("Warrants") exercisable at $0.001 per share in an amount equal to 20% of the principal amount of the tranche divided by the lowest traded price of our common stock during the 10 trading days preceding each funding date.

***November 13, 2025 Tranche***

On November 13, 2025, we entered into the first tranche of the SPA consisting of $500,000 principal with an original discount of $50,000 and legal fees totaling $12,500 for net proceeds to us of $437,500. In conjunction with this tranche, we issued Warrants to Mast Hill immediately exercisable for 1,538,461 shares of our common stock at $0.001 per share.

Due to the variability of the conversion feature, it is valued separately from the underlying debt as an embedded conversion feature, which is a derivative liability. Using the Black-Scholes pricing model, we determined the fair value of the derivative liability to be $495,717 at inception. The fair value of the derivative liability in excess of the available face value of the note, net of all discounts from other sources, was recorded as a day one financing cost totaling $137,410. The derivative liability was revalued at April 30, 2026 with an estimated fair value of $295,410. Accordingly, a gain on change in fair value of derivative liabilities in the amount of $221,335 and $200,307, respectively, was recorded on our Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the three and nine month periods ended April 30, 2026. See also Note 4.

At April 30, 2026, there was $437,320 of principal, $3,355 of accrued interest and warrants exercisable for 1,538,461 shares of our common stock outstanding pursuant to the November 13, 2025 tranche.

 ****

***December 31, 2025 Tranche***

On December 31, 2025, we entered into the second tranche of the SPA consisting of $500,000 principal with an original discount of $50,000 and legal fees totaling $12,500 for net proceeds to us of $437,500. In conjunction with this tranche, we issued Warrants to Mast Hill immediately exercisable for 3,508,771 shares of our common stock at $0.001 per share.

Due to the variability of the conversion feature, it is valued separately from the underlying debt as an embedded conversion feature, which is a derivative liability. Using the Black-Scholes pricing model, we determined the fair value of the derivative liability to be $548,321 at inception. The fair value of the derivative liability in excess of the available face value of the note, net of all discounts from other sources, was recorded as a day one financing cost totaling $192,620. The derivative liability was revalued at April 30, 2026 with an estimated fair value of $400,035. Accordingly, a gain on change in fair value of derivative liabilities in the amount of $174,243 and $148,286 respectively, was recorded on our Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the three and nine months ended April 30, 2026. See also Note 4.

At April 30, 2026, there was $500,000 of principal, $3,836 of accrued interest and warrants exercisable for 3,508,771 shares of our common stock outstanding pursuant to the December 31, 2025 tranche.

**August 27, 2025 Securities Purchase Agreement**

On August 27, 2025, we entered into a Securities Purchase Agreement (the "2025 SPA") with Mast Hill Fund L.P. ("Mast Hill"). Pursuant to the 2025 SPA, we sold Mast Hill (i) a $220,000 face value, one-year, 10% per annum Promissory Note (the "Note") convertible into shares of our common stock at 85% of the lowest volume-weighted average price of our common stock during the ten trading days immediately preceding the respective conversion date, and (ii) a five-year warrant that is immediately exercisable entitling Mast Hill to acquire 1,000,000 shares of our common stock at $0.10 per share. If the market price of our common stock is greater than the exercise price, Mast Hill may elect to receive warrant shares pursuant to a cashless exercise. Any principal or interest on this Note which is not paid when due shall bear interest at the rate of the lesser of (i) 16% per annum or (ii) the maximum rate permitted by law, from the due date thereof until the same is paid. Net proceeds after original discount of $22,000, fees and expenses was $190,500.

Due to the variability of the conversion feature, it is valued separately from the underlying debt as an embedded conversion feature, which is a derivative liability. Using the Black-Scholes pricing model, we determined the fair value of the derivative liability to be $647,574 at inception. The fair value of the derivative liability in excess of the available face value of the note, net of all discounts from other sources, was recorded as a day one financing cost totaling $507,368. The derivative liability was revalued at April 30, 2026 with an estimated fair value of $145,345. Accordingly, a gain on change in fair value of derivative liabilities in the amount of $77,828 and $502,229 respectively, was recorded on our Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the three and nine months ended April 30, 2026. See also Note 4.

At April 30, 2026, there was $220,000 of principal, $14,767 of accrued interest and warrants exercisable for 1,000,000 shares of our common stock outstanding pursuant to the 2025 SPA.

**July 29, 2025 Common Stock Purchase Agreement** 

Pursuant to an Equity Purchase Agreement (the "Agreement") dated July 29, 2025, we have the right, but not the obligation, to deliver Put Notices to Mast Hill Fund L.P. ("Mast Hill") to purchase Put Shares of our common stock totaling up to $25.0 million. Each Put Notice will be (i) in a minimum amount not less than $5,000 and (ii) in a maximum amount up to the lesser of (a) $500,000 or (b) 20% of the Average Daily Trading Value. The lesser of (a) or (b) is referred to as the Maximum Daily Put Amount. We may, at our option, specify a minimum share price with respect to our common stock (the "Minimum Price") in a Put Notice at the time that the Put Notice is delivered to Mast Hill.

To date, no Put Notices were delivered to Mast Hill under the Agreement.

**December 13, 2022 Securities Purchase Agreement**

Pursuant to the Securities Purchase Agreement with Mast Hill dated December 13, 2022 (the "2022 SPA"), on August 29, 2025, Mast Hill converted $80,618 of interest and $1,750 in fees for a total of $82,368 into 1,144,000 shares of our common stock at a price of $0.072 per share.

On October 9, 2025, we entered into Amendment No. 6 to the 2022 SPA, extending the maturity date for the full amount outstanding to April 30, 2026.

On June 9, 2026, we entered into Amendment No. 7 to the 2022 SPA, extending the maturity date for the full amount outstanding to October 31, 2026.

At April 30, 2026, there was $456,173 of principal, $124 of accrued interest and warrants exercisable for 14,666,667 shares of our common stock outstanding pursuant to the 2022 SPA.

***Directors and Officers Promissory Notes***

At April 30, 2026, we had $100,000 of principal and $34,839 of accrued interest related to these Promissory Notes outstanding and the due date has been extended to January 31, 2027.

***Notes Payable Summary***

The following notes payable were outstanding:

---

| | | |
|:---|:---|:---|
|  | **April 30,**<br>**2026** | **July 31,**<br>**2025** |
| Notes payable, officers and directors | $100000 | $100000 |
| Notes payable | 400000 | 300000 |
| Unamortized debt discount | (2656) | (512) |
| Notes payable, net | 397344 | 299488 |
| Convertible notes payable | 4816493 | 1584667 |
| Unamortized debt discount | (2671516) | – |
| Convertible notes payable, net | 2144977 | 1584667 |
| Total notes payable | 5316493 | 1984667 |
| Unamortized debt discount | (2674172) | (512) |
| Total notes payable outstanding, net | $2642321 | $1984155 |

---

**Note 6.&nbsp;&nbsp;&nbsp;&nbsp; Stock-Based Compensation**

 ****

***2021 Omnibus Stock Incentive Plan***

At April 30, 2026, 17,625,000 shares of our common stock were reserved for issuance pursuant to the 2021 Omnibus Stock Incentive Plan (the "2021 Plan") and 2,500,000 shares remained available for future awards under the 2021 Plan. ****

 ****

***Stock Options and Restricted Stock Units***

There was no restricted stock unit activity during the nine months ended April 30, 2026. Stock option activity during the nine months ended April 30, 2026 was as follows:

---

| | | |
|:---|:---|:---|
|  | **Number of Options** | **Weighted Average Exercise Price** |
| Options outstanding at July 31, 2025 | 17250000 | $0.16 |
| Options cancelled | (2400000) | $0.13 |
| Options outstanding at April 30, 2026 | 14850000 | $0.17 |

---

 ****

The weighted average contractual term remaining for outstanding stock options was 4.97 years at April 30, 2026.

 ****

***Warrants***

Warrant activity during the nine months ended April 30, 2026 was as follows:

---

| | | |
|:---|:---|:---|
|  | **Number of Warrants** | **Weighted Average Exercise Price** |
| Warrants outstanding at July 31, 2025 | 21475274 | $0.25 |
| Warrants issued | 6147232 | $0.02 |
| Warrants expired | (1604000) | $0.77 |
| Warrants outstanding at April 30, 2026 | 26018506 | $0.16 |

---

The weighted average contractual term remaining for outstanding warrants was 2.24 years at April 30, 2026.

***Unrecognized Compensation Costs***

At April 30, 2026, we had no unrecognized stock-based compensation.

**Note 7. Extinguishment of Accounts Payable**

During the quarter ended April 30, 2026, a total of $85,369 of accounts payable was forgiven by a total of five vendors. Pursuant to ASC 405-20, Liabilities, Extinguishment of Liabilities, this amount was recorded as Gain on extinguishment of accounts payable on our Condensed Consolidated Statements of Operations and Comprehensive Income (Loss).

**Note 8. Common Stock**

***Mast Hill Equity Purchase Agreement***

Pursuant to an Equity Purchase Agreement (the "Agreement") dated July 29, 2025, we have the right, but not the obligation, to deliver Put Notices to Mast Hill Fund L.P. to purchase Put Shares of our common stock totaling up to $25.0 million.

During the nine months ended April 30, 2026, no Put Notices were delivered to Mast Hill under the Agreement.

***Mast Hill Conversion of Interest and Fees***

On August 29, 2025, Mast Hill converted $80,618 of accrued interest and $1,750 in fees for a total of $82,368 into 1,144,000 shares of our common stock at a conversion price of $0.072 per share. See Note 5.

On March 25, 2026, Mast Hill converted $28,483 of accrued interest and $1,750 in fees for a total of $30,233 into 419,900 shares of our common stock at a conversion price of $0.072 per share. See Note 5.

On April 29, 2026, Mast Hill converted $43,494 of principal, $4,796 of accrued interest and $1,750 in fees for a total of $50,040 into 695,000 shares of our common stock at a conversion price of $0.072 per share. See Note 5.

 ****

***Conversion of LGH Investments, LLC Convertible Note***

On October 6, 2025, LGH converted $144,000 of principal from its outstanding convertible note into 2,000,000 shares of our common stock at a conversion price of $0.072 per share.

***Mast Hill Securities Purchase Agreement***

See Note 5. for a discussion of a November 13, 2025 SPA and related promissory note.

**Note 9. Earnings Per Share**

Basic earnings per share ("EPS") is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted EPS is computed based on the weighted average number of shares of common stock plus the effect of dilutive potential common shares outstanding during the period using the treasury stock and if-converted method. Dilutive potential common shares include outstanding stock options and stock awards.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended April 30,** | **Three Months Ended April 30,** | **Nine Months Ended April 30,** | **Nine Months Ended April 30,** |
|  | **2026** | **2025** | **2026** | **2025** |
| Net income (loss) attributable to common stockholders used for basic earnings (loss) per share | $765890 | $(251743) | $(3302742) | $(1490775) |
| &nbsp;&nbsp;&nbsp;Add back convertible debt interest | 83650 |  |  |  |
| &nbsp;&nbsp;&nbsp;Add back convertible debt amortization | 391136 | – | – | – |
| Net income (loss) attributable to common stockholders used for diluted earnings (loss) per share calculations | $1240676 | $(251743) | $(3302742) | $(1490775) |
| Weighted average outstanding shares of common stock used for basic earnings (loss) per share | 108031419 | 104709763 | 107299314 | 104709763 |
| &nbsp;&nbsp;&nbsp;Dilutive effect of convertible debt | 73680582 |  |  |  |
| &nbsp;&nbsp;&nbsp;Dilutive effect of warrants | 4962906 | – | – | – |
| Common stock and common stock equivalents used for diluted earnings (loss) per share | 186674907 | 104709763 | 107299314 | 104709763 |
| **Earnings (Loss) Per Share** |  |  |  |  |
| Basic | $0.01 | $(0.00) | $(0.03) | $(0.01) |
| Diluted | $0.01 | $(0.00) | $(0.03) | $(0.01) |

---

The following anti-dilutive securities were excluded from the calculations of diluted net loss per share:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended April 30,** | **Three Months Ended April 30,** | **Nine Months Ended April 30,** | **Nine Months Ended April 30,** |
|  | **2026** | **2025** | **2026** | **2025** |
| Options to purchase common stock | 14850000 | 17620000 | 14850000 | 17620000 |
| Shares issuable upon conversion of convertible notes and related accrued interest | 24170897 | 26536748 | 24170897 | 26536748 |
| Warrants to purchase common stock | 20971274 | 21475274 | 20971274 | 21475274 |
| Total potentially dilutive securities | 59992171 | 65632022 | 59992171 | 65632022 |

---

**Note 10. Related Party Transactions**

***Accounts Payable and Accrued Wages, Officers***

Accounts payable and accrued wages, officers included the following:

---

| | | |
|:---|:---|:---|
|  | **April 30, 2026** | **July 31, 2025** |
| Reimbursement of expenses: |  |  |
| &nbsp;&nbsp;&nbsp;Joseph M. Redmond, CEO | $– | $17125 |
| &nbsp;&nbsp;&nbsp;Christine Farrell, CFO | – | 34085 |
|  |  | 51210 |
| Accrued salary and bonus: |  |  |
| &nbsp;&nbsp;&nbsp;Joseph M. Redmond, CEO | 1360769 | 1330308 |
| &nbsp;&nbsp;&nbsp;Christine Farrell, CFO | 493848 | 476925 |
|  | 1854617 | 1807233 |
|  | $1854617 | $1858443 |

---

See Note 5 for a discussion of $25,000 Promissory Notes payable to each of our Chief Executive Officer, Chief Financial Officer, and two directors, for an aggregate principal amount of $100,000.

**Note 11. Subsequent Events**

***Termination of BreastCheck Agreement***

On May 6, 2026, we received formal written notice from NeuRX, advising us that NeuRX was in breach of its contractual obligations with Davion Healthcare Plc ("Davion"). Specifically, NeuRX failed to obtain Davion's required approval prior to sublicensing the BreastCheck product to us. As a result, the notice stated that the Agreement between us and NeuRX was immediately cancelled.

***Termination of Australian Subsidiary***

On May 20, 2026, we dissolved our Australian subsidiary, Odyssey Group International Pty.

***Amendments to Convertible Debt***

On May 18, 2026, and effective April 30, 2026, we entered into Amendment No. 12 to the Convertible Promissory Note with LGH Investments LLC, extending the maturity date for the full amount outstanding to September 30, 2026.

On June 9, 2026, and effective April 30, 2026, we entered into Amendment No. 7 to the 2022 SPA with Mast Hill Fund, L.P., extending the maturity date for the full amount outstanding to October 31, 2026.

**Item 2.** ***Management's Discussion and Analysis of Financial Condition and Results of Operations***

**CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS**

This quarterly report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical fact, included in this report regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management are forward-looking statements. The words "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that the expectations underlying our forward-looking statements are reasonable, these expectations may prove to be incorrect, and all of these statements are subject to risks and uncertainties. Therefore, you should not place undue reliance on our forward-looking statements.

Many possible events or factors could affect our future financial results and performance and could cause actual results or performance to differ materially from those expressed, including those risks and uncertainties described in Part I, Item 1A. "Risk Factors" in our Annual Report on Form 10-K for the year ended July 31, 2025 ("2025 Annual Report") and those described from time to time in our future reports filed with the Securities and Exchange Commission (the "SEC"). We believe these risks and uncertainties could cause actual results or events to differ materially from the forward-looking statements that we make. Should one or more of these risks and uncertainties materialize, or should underlying assumptions, projections or expectations prove incorrect, actual results, performance or financial condition may vary materially and adversely from those anticipated, estimated or expected. Our forward-looking statements do not reflect the potential impact of future acquisitions, mergers, dispositions, joint ventures or investments that we may make. We do not assume any obligation to update any of the forward-looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law. In the light of these risks and uncertainties, the forward-looking events and circumstances discussed in this report may not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements.

**Overview**

Our business model is to develop or acquire unique medical-related products, engage third parties to develop and manufacture such products and then distribute the products through various distribution channels, including third parties. We have two different technologies in the research and development stage; the CardioMap heart monitoring and screening device, and the Save-A-Life choking rescue device. To date, none of our product candidates have received regulatory clearance or approval for commercial sale.

Upon receiving adequate funding, we plan to license and develop our products and identify other product potentials we can develop or acquire. We will then engage third-party research and development firms that specialize in creating products to assist us, and we will apply for trademarks and patents at appropriate product development advances.

**Recent Funding**

 ****

***$100,000 Promissory Note***

On October 3, 2025, we entered into a $100,000 promissory note with an effective date of October 1, 2025, with Peter D'Arruda, a non-affiliated accredited investor. The $100,000 was received October 3, 2025. The note has a one-year maturity, becoming due on September 30, 2026, and bears interest at the rate of 18% per annum. In addition, we issued the investor an immediately exercisable warrant to purchase 100,000 shares of our common stock at $0.10 per share that expires September 30, 2030.

***Mast Hill Fund L.P.***

 ****

**August 27, 2025 Securities Purchase Agreement**

On August 27, 2025, we received net proceeds of $190,500 pursuant to a Securities Purchase Agreement with Mast Hill. See Note 5 of Notes to Condensed Consolidated Financial Statements for additional information.

**November 13, 2025 Securities Purchase Agreement Tranche**

On November 13, 2025, we entered into the first tranche of the November 13, 2025, Securities Purchase Agreement with Mast Hill and received net proceeds of $437,500. See Note 5 of Notes to Condensed Consolidated Financial Statements for additional information.

**December 31, 2025 Securities Purchase Agreement Tranche**

On December 31, 2025, we entered into the second tranche of the November 13, 2025, Securities Purchase Agreement with Mast Hill and received net proceeds of $437,500. See Note 5 of Notes to Condensed Consolidated Financial Statements for additional information.

**Going Concern**

See Note 1 of Notes to Condensed Consolidated Financial Statements.

**Significant Accounting Policies and Use of Estimates** 

Other than as described in Note 1 of Notes to Condensed Consolidated Financial Statements, during the nine months ended April 30, 2026, there were no significant changes to our significant accounting policies and estimates as described in Note 2. *Summary of Significant Accounting Policies* included in Part II, Item 8. of our Annual Report on Form 10-K for the year ended July 31, 2025, which was filed with the SEC on October 29, 2025.

**Results of Operations**

We provide maintenance and related services for a commercial facility pursuant to our Maintenance Agreement with Mast Hill Fund, L.P. beginning November 13, 2025 and ending on the first business day of February 2034. In exchange, Mast Hill pays us service fees which currently total approximately $252,450 per year. We do not currently sell or market any products. The service fees are recorded as an offset to the Maintenance note principal and accrued interest. We will commence actively marketing products after the products and drugs in development have been FDA cleared or approved, but there can be no assurance, however, that we will be successful in obtaining FDA clearance or approval for our products.

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended <br> April 30,** | **Three Months Ended <br> April 30,** | |
|  | **2026** | **2025** | **%**<br>**Change** |
| General and administrative expense | $297554 | $129055 | 130.6% |
| Loss from operations | (297554) | (129055) | 130.6% |
| Loss from change in fair value of Oragenics, Inc. common stock |  | (61357) | -100.0% |
| Interest expense | (527551) | (61395) | 759.3% |
| Change in fair value of derivative liability | 1505581 |  | 100.0% |
| Extinguishment of debt | 85369 |  | 100.0% |
| Other income expense, net | 45 | 64) | -29.7% |
| Net income (loss) attributable to common shareholders | $765890 | $(251743) | -404.2% |
| Basic net income (loss) and comprehensive income (loss) per share | $0.01 | $0.00 | nm |
| Diluted net income (loss) and comprehensive income (loss) per share | $0.01 | $0.00 | nm |

---

---

| | | | |
|:---|:---|:---|:---|
|  | **Nine Months Ended <br> April 30,** | **Nine Months Ended <br> April 30,** | |
|  | **2026** | **2025** | **%**<br>**Change** |
| General and administrative expense | $782687 | $865075) | -9.5% |
| Loss from operations | (782687) | (865075) | -9.5% |
| Loss from change in fair value of Oragenics, Inc. common stock |  | (432053) | -100.0% |
| Interest expense | (1035315) | (193611) | 434.7% |
| Financing costs | (3080023) | –) | 100.0% |
| Change in fair value of derivative liability | 1503652 |  | 100.0% |
| Extinguishment of debt | 85369 |  | 100.0% |
| Other expense, net | (10177) | (36) | 28169.4% |
| Net loss attributable to common shareholders | $(3319181) | $(1490775) | 122.6% |
| Basic net loss and comprehensive loss per share | $(0.03) | $(0.01) | 200.0% |
| Diluted net loss and comprehensive loss per share | $(0.03) | $(0.01) | 200.0% |

---

nm: Not meaningful

***General and Administrative Expense***

General and administrative expense includes expenses related to salaries and related benefits for employees in finance, accounting, sales, administrative, and research and development activities, as well as stock-based compensation, costs related to maintaining compliance as a public company, and legal and professional fees.

The net decreases in General and administrative expense were due to the following:

---

| | | |
|:---|:---|:---|
|  | **Three months**<br> **ended**<br> **April 30, 2026**<br> **compared to**<br> **three months**<br> **ended**<br>**April 30, 2025** | **Nine months <br>ended <br>April 30, 2026 <br>compared to<br> nine months<br> ended**<br>**April 30, 2025** |
| **Increase (decrease) in:** |  |  |
| Business development and investor relations | $64100 | $255600 |
| Insurance expense | (1544) | (7151) |
| Legal and professional fees | (9866) | (24518) |
| Public company expense | 9926 | (186539) |
| Stock-based compensation | (11781) | (108399) |
| Travel | 4971 | 8809 |
| Wages | 114103 | 1618 |
| Bad debt expense | (5000) | (26616) |
| Other | 3590 | 4808 |
|  | $168499 | $(82388) |

---

The decrease in public company expense for the nine months ended April 30, 2026 was due to lower securities filing activity. The increase in wages for the three months ended April 30, 2026 was due to full wages being paid to our officers. The increase in wages for the nine months ended April 30, 2026 was offset by a voluntary decrease in executive salaries in the first two quarters of Fiscal 2026. The decreases in stock-based compensation were due to no stock-based compensation in the three and nine months of fiscal 2026 due to no equity awards being granted and no unrecognized stock-based compensation. The increases in business development and investor relations expense primarily related to our agreement with NeuRX Health, Inc. and associated investor relations outreach. See Note 3 of Notes to Condensed Consolidated Financial Statements.

 ****

***Loss from Change in Fair Value of Oragenics, Inc. Common Stock***

Loss from change in fair value of Oragenics, Inc. common stock in the prior year period related to the value of the common stock of Oragenics that was held by us as an investment. All shares were sold during fiscal 2025. ****

 ****

***Interest Expense***

Interest expense includes interest on debt outstanding, as well as the amortization of debt discount and debt issuance costs. Certain information regarding debt outstanding was as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended April 30,** | **Three Months Ended April 30,** | **Nine Months Ended April 30,** | **Nine Months Ended April 30,** |
|  | **2026** | **2025** | **2026** | **2025** |
| Weighted average debt outstanding | $5359499 | $1909329 | $4032280 | $1782230 |
| Weighted average interest rate | 10.23% | 10.36% | 9.31% | 11.10% |

---

***Financing Costs***

Financing costs in fiscal 2026 included the following:

---

| | |
|:---|:---|
|  | **Fiscal 2026** |
| &nbsp;&nbsp;&nbsp;August 27, 2025 Mast Hill Securities Purchase Agreement | $507368 |
| Total in three months ended October 31, 2025 | 507368 |
| &nbsp;&nbsp;&nbsp;November 13, 2025 Mast Hill Maintenance SPA Convertible Promissory Note | 2242625 |
| &nbsp;&nbsp;&nbsp;November 13, 2025 Mast Hill SPA Tranche | 137410 |
| &nbsp;&nbsp;&nbsp;December 31, 2025 Mast Hill SPA Tranche | 192620 |
| Total in six months ended January 31, 2026 | 3080023 |
| Total in nine months ended April 30, 2026 | $3080023 |

---

 ****

***Change in Fair Value of Derivative Liability***

Change in fair value of derivative liabilities in the Fiscal 2026 periods relates to the value of the variable conversion features embedded in our August 27, 2025 SPA and November 13, 2025 SPA with Mast Hill. See Notes 4 and 5 of Notes to Condensed Consolidated Financial Statements for additional information.

***Gain on Extinguishment of Accounts Payable***

Gain on extinguishment of accounts payable in the Fiscal 2026 periods relates to a total of $85,369 of accounts payable and accrued wages that were forgiven by a total of five vendors.

**Liquidity and Capital Resources**

See Recent Funding above for a discussion of our recent financings.

The following table sets forth the primary sources and uses of cash:

---

| | | |
|:---|:---|:---|
|  | **Nine Months Ended April 30,** | **Nine Months Ended April 30,** |
|  | **2026** | **2025** |
| Net cash used in operating activities | $(886778) | $(299193) |
| Net cash provided by financing activities | 1165500 | 300000 |

---

To date, we have financed our operations primarily through debt financing and limited sales of our common stock. Our ability to continue to access capital could be affected adversely by various factors, including general market and other economic conditions, interest rates, the perception of our potential future earnings and cash distributions, any unwillingness on the part of lenders to make loans to us and any deterioration in the financial position of lenders that might make them unable to meet their obligations to us. If these conditions continue and we cannot raise funds through a public or private debt financing, or an equity offering, our ability to grow our business may be negatively affected. In such case, we have suspended research and development activities until market conditions improve.

***Debt***

The following notes payable were outstanding:

---

| | | |
|:---|:---|:---|
|  | **April 30,**<br>**2026** | **July 31,**<br>**2025** |
| Notes payable, officers and directors | $100000 | $100000 |
| Notes payable | 400000 | 300000 |
| Unamortized debt discount | (2656) | (512) |
| Notes payable, net | 397344 | 299488 |
| Convertible notes payable | 4816493 | 1584667 |
| Unamortized debt discount | (2671516) | – |
| Convertible notes payable, net | 2144977 | 1584667 |
| Total notes payable | 5316493 | 1984667 |
| Unamortized debt discount | (2674172) | (512) |
| Total notes payable outstanding, net | $2642321 | $1984155 |

---

**Inflation**

Inflation did not have a material impact on our business and results of operations during the periods being reported on.

**Off Balance Sheet Arrangements**

We do not have any material off balance sheet arrangements.

**Item 3.** ***Quantitative and Qualitative Disclosures About Market Risk***

We are a smaller reporting company and are not required to provide information under this item.

**Item 4.** ***Controls and Procedures***

**Evaluation of Disclosure Controls and Procedures**

Management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of April 30, 2026. The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives. Based on the evaluation of our disclosure controls and procedures as of April 30, 2026, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, as a result of the material weaknesses in internal control over financial reporting that are described below, our disclosure controls and procedures were not effective.

As previously reported in our Annual Report on Form 10-K for the fiscal year ended July 31, 2025, management identified the following material weaknesses in internal control over financial reporting:

*Insufficient Resources:* We have an inadequate number of personnel with requisite expertise in the key functional areas of finance and accounting.

*Inadequate Segregation of Duties*: We have an inadequate number of personnel to properly implement control procedures.

We are committed to improving the internal controls and will (1) continue to use third party specialists to address shortfalls in staffing and to assist us with accounting and finance responsibilities, (2) increase the frequency of independent reconciliations of significant accounts, which will mitigate the lack of segregation of duties until there are sufficient personnel, and (3) may consider appointing additional outside directors and audit committee members in the future.

In light of the material weaknesses described above, prior to the filing of this Form 10-Q for the period ended April 30, 2026, management determined that key quarterly controls were performed timely and also performed additional procedures, including validating the completeness and accuracy of the underlying data used to support the amounts reported in the quarterly financial statements. These control activities and additional procedures have allowed us to conclude that, notwithstanding the material weaknesses, the financial statements in this Form 10-Q fairly present, in all material respects, our financial position, results of operations, and cash flows for the periods presented in conformity with United States GAAP.

**Changes in Internal Control Over Financial Reporting**

There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

**PART II - OTHER INFORMATION**

---

| | |
|:---|:---|
| **Item 1A.** | ***Risk Factors*** |

---

There have been no material changes during the nine months ended April 30, 2026, to the risk factors discussed in our Annual Report on Form 10-K for the year ended July 31, 2025. If any of the identified risks actually occur, our business, financial condition and results of operations could suffer. The trading price of our common stock could decline and you may lose all or part of your investment in our common stock. The risks and uncertainties described in our Annual Report on Form 10-K for the year ended July 31, 2025, are not the only ones we face. Additional risks that we currently do not know about or that we currently believe to be immaterial may also impair our business operations.

**Item 5.** ***Other Information***

During the quarter ended April 30, 2026, no director or officer adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K.

**Item 6.** ***Exhibits***

 ****

The following exhibits are filed herewith and this list constitutes the exhibit index.

---

| | |
|:---|:---|
| **Exhibit Number** | **Exhibit Description** |
| 10.1 | [Master Technology and Sub-License Agreement between Odyssey Health, Inc. and NeuRX Health, Inc](https://www.sec.gov/Archives/edgar/data/1626644/000168316825007644/odyssey_ex1001.htm) (incorporated by reference to Exhibit 10.1 to Form 8-K filed with the SEC on October 17, 2025). |
| 10.2 | [Amendment No. 1, dated April 21, 2026, to the Master Technology and Sub-License Agreement dated October 14, 2025](https://www.sec.gov/Archives/edgar/data/1626644/000168316826003205/odyssey_ex1002.htm) (incorporated by reference to Exhibit 10.2 to Form 8-K filed with the SEC on April 24, 2026). |
| 10.3 | [NeuRX Health, Inc. Revocation Letter dated May 6, 2026](https://www.sec.gov/Archives/edgar/data/0001626644/000168316826003682/odyssey_ex1001.htm) (incorporated by reference to Exhibit 10.1 to Form 8-K filed with the SEC on May 11, 2026) |
| 10.4 | [Form of Amendment No. 12 dated January 30, 2026, to Convertible Promissory Note with Directors and Officers, dated December 21, 2021 and December 22, 2021](https://www.sec.gov/Archives/edgar/data/0001626644/000168316826000730/odyssey_ex1001.htm) (incorporated by reference to Exhibit 10.1 to Form 8-K filed with the SEC on February 3, 2026) |
| 10.5 | [Amendment No. 11 dated January 30, 2026 to Convertible Promissory Note with LGH Investments, LLC dated April 5, 2021](https://www.sec.gov/Archives/edgar/data/1626644/000168316826000730/odyssey_ex1002.htm) (incorporated by reference to Exhibit 10.2 to Form 8-K filed with the SEC on February 3, 2025). |
| 10.6 | [Amendment No. 5 dated January 30, 2026, to the Promissory Note with accredited investor Jonathan Lutz, dated February 13, 2024](https://www.sec.gov/Archives/edgar/data/0001626644/000168316826000730/odyssey_ex1003.htm) (incorporated by reference to Exhibit 10.3 to Form 8-K filed with the SEC on February 3, 2025) |
| 10.7 | [Amendment No. 2 dated February 2, 2026 and effective January 30, 2026, to the Promissory Note with accredited investor Peter J. D'Arruda, dated August 14, 2024](https://www.sec.gov/Archives/edgar/data/1626644/000168316826000730/odyssey_ex1004.htm) (incorporated by reference to Exhibit 10.4 to Form 8-K filed with the SEC on February 3, 2026) |
| 10.8 | [Amendment No. 12 dated May 18, 2026 to Convertible Promissory Note with LGH Investments, LLC dated April 5, 2021](https://www.sec.gov/Archives/edgar/data/1626644/000168316826004280/odyssey_ex1001.htm) (incorporated by reference to Exhibit 10.1 to Form 8-K filed with the SEC on May 26, 2026). |
| 10.9 | [Amendment No. 6 dated October 9, 2025 to Promissory Note issued December 13, 2022 with Mast Hill Fund, L.P](https://www.sec.gov/Archives/edgar/data/1626644/000168316825007502/odyssey_ex1001.htm) (incorporated by reference to Exhibit 10. 1 to Form 8-K filed with the SEC on October 10, 2025) |
| 10.10 | [Amendment No. 7 dated June 9, 2026 to Promissory Note issued December 13, 2022 with Mast Hill Fund, L.P.](odyssey_ex1010.htm)\*\* |
| 31.1 | [Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934](odyssey_ex3101.htm) |
| 31.2 | [Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934](odyssey_ex3102.htm) |
| 32.1 | [Certification of Chief Executive Officer pursuant to Section 1350](odyssey_ex3201.htm) |
| 32.2 | [Certification of Chief Financial Officer pursuant to Section 1350](odyssey_ex3202.htm) |
| 101.INS | Inline XBRL Instances Document |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover Page Interactive Data File (formatted in iXBRL, and included in exhibit 101). |

---

\*\* Filed herewith

**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized, as of June 12, 2026.

---

| | |
|:---|:---|
| **ODYSSEY HEALTH, INC.** | **ODYSSEY HEALTH, INC.** |
| By: | /s/ Joseph Michael Redmond |
|  | Joseph Michael Redmond |
|  | Chief Executive Officer, President and Director |
|  | (Principal Executive Officer) |
| By: | /s/ Christine M. Farrell |
|  | Christine M. Farrell |
|  | Chief Financial Officer |
|  | (Principal Financial and Accounting Officer) |

---

## Exhibit 10.10

**Exhibit 10.10**

**AMENDMENT #7 TO THE PROMISSORY NOTE**

**ISSUED ON DECEMBER 13, 2022**

THIS AMENDMENT #7 to the Note (as defined below) (the "Amendment") is entered into as of June 9, 2026, and made effective as of April 30, 2026 (the "Effective Date"), by and between ODYSSEY HEALTH, INC., a Nevada corporation (the "Company"), and MAST HILL FUND, L.P., a Delaware limited partnership (the "Holder") (collectively the "Parties").

**BACKGROUND**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A. The Company and Holder are the parties to that certain promissory
note originally issued by the Company to the Holder on December 13, 2022, in the original principal amount of $870,000.00 (as amended
from time to time, the "Note"); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B. The Parties entered into that certain pledge agreement on December 28, 2023 (the
"Pledge Agreement"); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C. The Parties desire to amend the Note as set forth expressly below.

NOW THEREFORE, in consideration of the execution and delivery of the Amendment and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The Maturity Date (as defined in the Note) of the Note shall be extended to October 31, 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. This Amendment shall be deemed part of, but shall take precedence over and supersede any provisions to the contrary contained in the Note. Except as specifically modified hereby, all of the provisions of the Note, which are not in conflict with the terms of this Amendment, shall remain in full force and effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. This Amendment may be executed in two or more counterparts, each of which when so executed and delivered to the other party shall be deemed an original. The executed page(s) from each original may be joined together and attached to one such original and shall thereupon constitute one and the same instrument. Such counterparts may be delivered by facsimile or other electronic transmission, which shall not impair the validity thereof.

*[Signature page to follow]*

 

 

 

IN WITNESS WHEREOF, the Parties hereto have executed this Amendment as of the date first above written.

---

| | |
|:---|:---|
| **ODYSSEY HEALTH, INC.** | **MAST HILL FUND, L.P.** |
| By: <u>/s/ Joseph Redmond</u> | By:<u>/s/ Patrick Hassani</u> |
| Name: Joseph Redmond | Name: Patrick Hassani |
| Title: Chief Executive Officer | Title: Chief Investment Officer |

---

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION**

I, Joseph Michael Redmond, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this Form 10-Q of Odyssey Health, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| June 12, 2026 | /s/ Joseph Michael Redmond |
|  | Joseph Michael Redmond |
|  | Chief Executive Officer, President and Director<br> (Principal Executive Officer) |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION**

I, Christine M. Farrell, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this Form 10-Q of Odyssey Health, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| June 12, 2026 | /s/ Christine M. Farrell |
|  | Christine M. Farrell |
|  | Chief Financial Officer<br> (Principal Financial and Accounting Officer) |

---

## Exhibit 32.1

**Exhibit 32.1**

**Certification Pursuant to 18 U.S.C. Section 1350**

In connection with the Quarterly Report of Odyssey Health, Inc. (the "Company") on Form 10-Q for the three months ended April 30, 2026 as filed with the Securities and Exchange Commission (the "SEC") on or about the date hereof (the "Report"), I, Joseph Michael Redmond, Chief Executive Officer, President and Director of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement has been provided to the Company and will be retained by the Company and furnished to the SEC or its staff upon request.

---

| | |
|:---|:---|
| June 12, 2026 | /s/ Joseph Michael Redmond |
|  | Joseph Michael Redmond |
|  | Chief Executive Officer, President and Director<br> (Principal Executive Officer) |

---

## Exhibit 32.2

**Exhibit 32.2**

**Certification Pursuant to 18 U.S.C. Section 1350**

In connection with the Quarterly Report of Odyssey Health, Inc. (the "Company") on Form 10-Q for the three months ended April 30, 2026 as filed with the Securities and Exchange Commission (the "SEC") on or about the date hereof (the "Report"), I, Christine M. Farrell, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement has been provided to the Company and will be retained by the Company and furnished to the SEC or its staff upon request.

---

| | |
|:---|:---|
| June 12, 2026 | /s/ Christine M. Farrell |
|  | Christine M. Farrell |
|  | Chief Financial Officer<br> (Principal Financial and Accounting Officer) |

---